Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

Which drugmaker holds the better potential for your portfolio? Bristol Myers Squibb (NYSE:BMY) and Pfizer (NYSE:PFE) both face a decade of patent cliffs and shifting regulatory landscapes in the healthcare sector.

Bristol Myers Squibb focuses on specialized medicines for serious diseases like cancer, while Pfizer operates a massive global portfolio spanning vaccines and primary care. Both companies are navigating the post-pandemic era by acquiring new drug pipelines. Comparing these giants helps clarify which path offers the more attractive balance of risk and reward for investors.

The case for Bristol Myers Squibb

Bristol Myers Squibb focuses on discovering and developing innovative medicines for serious diseases, with leadership in oncology, hematology, and neuroscience among pharmaceutical stocks. The company distributes its products globally to major markets like the United States and China through wholesalers and specialty pharmacies. It also maintains strategic alliances with Ono, Zai Lab (NASDAQ:ZLAB), BioNTech (NASDAQ:BNTX), Johnson & Johnson (NYSE:JNJ), Zenas BioPharma (NASDAQ:ZBIO), and Merck (NYSE:MRK).

In FY 2025, revenue reached nearly $48.2 billion. This was a slight decrease of roughly 0.2% compared to the previous year. Net income for the period was close to $7.1 billion, a recovery from the net loss reported in the prior fiscal year, resulting in a net margin of approximately 14.6%.

As of its December 2025 balance sheet, the debt-to-equity ratio is roughly 2.6x. This figure, which compares total debt to shareholder equity, indicates how much the company uses borrowing to fund its operations. The current ratio, which measures the ability to cover short-term liabilities with short-term assets, is approximately 1.3x. Free cash flow, which is cash from operations minus capital expenditures, was nearly $12.8 billion.

The case for Pfizer

Pfizer operates as a massive biopharmaceutical entity that discovers, manufactures, and delivers medicines and vaccines to patients in approximately 200 countries. Its business relies on significant collaborations, such as its partnership with BioNTech for the Comirnaty vaccine. The company also works with generic manufacturers like Dexcel Pharma, Hikma Pharmaceuticals (OTC:HKMPF), and Cipla to manage patent life cycles.

In FY 2025, revenue reached nearly $62.6 billion. This represented a year-over-year decrease of nearly 1.6%. Net income reached close to $7.8 billion, leading to a net margin of approximately 12.4%, which was a small decrease from the net income recorded during the previous year.

As of its December 2025 balance sheet, the debt-to-equity ratio is approximately 0.8x. This ratio, which measures total debt against shareholder equity, suggests a relatively conservative use of borrowing. The current ratio, a measure of a company's ability to pay short-term obligations with short-term assets, is approximately 1.2x. Free cash flow for the year was roughly $9.1 billion.

Risk profile comparison

Bristol Myers Squibb faces intense pricing pressure from the Inflation Reduction Act, which has led to Medicare-set prices for products like Eliquis and Pomalyst. Patent expirations for major products remain a primary concern, alongside ongoing generic and biosimilar competition. The company also deals with significant legal exposure, including a recently revived $6.7 billion lawsuit regarding contingent value rights linked to its Celgene acquisition. Additionally, the company faces inherent risks in its oncology pipeline, highlighted by the recent termination of an early-stage leukemia clinical trial.

Pfizer faces major risks including the evolving impact of the Inflation Reduction Act on revenue for high-expenditure drugs, alongside significant patent cliffs through 2030. The company faces substantial legal and regulatory overhang, including a $44 million settlement for Chantix and a massive confidential settlement covering federal lawsuits regarding Depo-Provera. There is also a lawsuit from the Florida Attorney General concerning vaccine marketing and patent litigation involving Bayer.

Valuation comparison

Bristol-Myers Squibb appears slightly more affordable on a forward earnings basis, though both companies trade at identical revenue multiples.

Valuation metrics include sourcing from Financial Modeling Prep (FMP) and may differ from other data providers.

Which stock would I buy in 2026?

I'd go with Pfizer. Both companies are navigating patent cliffs, but Pfizer is building a clearer picture of what comes next. Non-COVID products are growing at an encouraging rate, a recent acquisition puts it in the obesity drug race alongside Eli Lilly and Novo Nordisk, and several key pipeline readouts are expected over the next 12 months. And I like that management has committed to protecting and growing the dividend through this transition.

Bristol Myers Squibb has had a rough year in the market, but the underlying business is showing signs of improvement. The company just raised its full-year revenue outlook and newer growth brands are gaining traction. Eliquis continues to defy expectations with stronger-than-anticipated growth. For investors who want a healthcare stock with improving near-term momentum, it deserves a closer look.

But BMS still faces significant revenue pressure from patent losses in the years ahead, and drug pricing reforms add uncertainty that is hard to plan around. While Pfizer is asking investors to wait for its pipeline to deliver, BMS is asking investors to wait through an even longer stretch of uncertainty. For me, Pfizer's more visible post-patent roadmap makes it the slightly more comfortable pick.

Sara Appino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends BioNTech Se, Bristol Myers Squibb, Eli Lilly, Merck, Novo Nordisk, and Pfizer. The Motley Fool recommends Hikma Pharmaceuticals Plc. The Motley Fool has a disclosure policy.